April 2010
Volume 51, Issue 13
ARVO Annual Meeting Abstract  |   April 2010
Transglutaminase Inhibitor, Cysteamine Attenuates Experimental Autoimmune Uveitis in Mice
Author Affiliations & Notes
  • T. Kim
    Ophthalmology, Seoul National University Hospital, Seoul, Republic of Korea
    Ophthalmology, Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul, Republic of Korea
  • H. Chung
    Ophthalmology, Seoul National Univ Sch of Med, Seoul, Republic of Korea
  • H. G. Yu
    Ophthalmology, Seoul National Univ Hospital, Seoul, Republic of Korea
  • Footnotes
    Commercial Relationships  T. Kim, None; H. Chung, None; H.G. Yu, None.
  • Footnotes
    Support  a grant for Research on Korea Health Industry Development Institute A084448
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 5236. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      T. Kim, H. Chung, H. G. Yu; Transglutaminase Inhibitor, Cysteamine Attenuates Experimental Autoimmune Uveitis in Mice. Invest. Ophthalmol. Vis. Sci. 2010;51(13):5236.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

The purpose of the present study was to investigate the effect of cysteamine on experimental autoimmune uveitis (EAU) in mice and provide new insights for the treatment of human uveitis.


EAU was induced in female C57BL/6 wild-type mice by a footpad injection of human IRBP1-20 (250ug/mouse) emulsified in complete Freud adjuvant (CFA). From one day before the IRBP inoculation, cysteamine, TG inhibitor was daily administered by intraperitoneal injection. Control group received the same amount of vehicle only. After 1 week, the draining lymph nodes were collected, and T lymphocytes were analyzed for cytokine assay by intracellular staining. In addition, clinical, histopathology, and TG activity were analyzed.


A single immunization of IRBP peptide led to cellular infiltrates and significant structural damage of the retina. Disease onset was significantly delayed in cysteamine-treated mice (14.6 days) compared to untreated mice (12.1 days, p=0.02). The number of inflammatory cells, the TG activity, and the levels of Th1 and Th17-type cytokines in the groups treated with cysteamine were decreased. Alteration was not found in Th2-type cytokines. The cytokine expression was correlated with the inflammatory activity.


The results suggest that cysteamine has an anti-inflammatory effect that is due to the blocking of the expression of Th1 and Th17 cytokines. This finding demonstrated the therapeutic potential of cysteamine for the control of endogenous ocular inflammatory diseases.  

Keywords: uveitis-clinical/animal model • cytokines/chemokines • inflammation 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.